Treatment of intestinal protozoan infections in children
- 1Academic Paediatric Hospital “Pedro Borrás”, Havana City, Cuba
- 2National Centre of Education and Health Promotion, Havana City, Cuba
- 3National Institute of Hygiene, Epidemiology and Microbiology, Havana City, Cuba
- 4Institute of Infectious Diseases “Emilio Ribas”, São Paulo, Brazil
- 5Atlantic International University, Honolulu, Hawaii, USA
- Dr Angel A Escobedo, Hospital Pediátrico Universitario “Pedro Borrás”, Calle F No. 616 esquina a 27, Plaza, Ciudad de La Habana, CP 10400, Cuba; escobedo{at}infomed.sld.cu
- Accepted 10 February 2009
- Published Online First 26 March 2009
Abstract
Intestinal protozoan infections are a worldwide problem in both industrialised and unindustrialised countries; in the latter they may be the cause of significant morbidity and mortality. Children, in particular, are more likely to experience considerable morbidity. Most intestinal protozoan infections can cause acute or chronic diarrhoea in healthy individuals and may result in intractable, life-threatening illness in patients with immunosuppressive diseases such as AIDS. Adequate identification and treatment of these infections may provide significant benefit for individual patients and public health. This article presents an update on the pharmacotherapy currently available for amoebiasis, giardiasis and other intestinal protozoan infections.
Footnotes
-
Competing interests: None.








